Your session is about to expire
← Back to Search
Monoclonal Antibodies
LY3972406 for Psoriasis
Phase 2
Recruiting
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Are able to swallow oral medication
Be older than 18 years old
Must not have
Have a current or recent acute, active infection
Have any other skin conditions, excluding plaque psoriasis
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Summary
This trial is testing a new medication called LY3972406 to see if it can help adults with moderate-to-severe plaque psoriasis. The goal is to find out if it works well and is safe to use. Plaque psoriasis causes red, scaly patches on the skin, and this medication aims to reduce these symptoms.
Who is the study for?
This trial is for adults who've had moderate-to-severe chronic plaque psoriasis for at least 6 months. Participants must be able to swallow pills, allow blood sampling, and agree to skin biopsies. It's not open to those with other skin conditions or autoimmune diseases, active infections, or women who are breastfeeding.
What is being tested?
The study is testing the effectiveness and safety of a new medication called LY3972406 compared to a placebo in treating plaque psoriasis. Participants will randomly receive either the actual drug or a placebo without knowing which one they're getting.
What are the potential side effects?
While specific side effects of LY3972406 aren't listed here, common side effects from medications treating psoriasis may include irritation at the application site, headaches, fatigue, nausea and potential impacts on liver function.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I can take pills by mouth.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I currently have or recently had a serious infection.
Select...
I have a skin condition other than plaque psoriasis.
Select...
I have an autoimmune disease like lupus.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Trial Design
3Treatment groups
Experimental Treatment
Placebo Group
Group I: LY3972406 Dose 2Experimental Treatment1 Intervention
Participants will receive an oral dose of LY3972406
Group II: LY3972406 Dose 1Experimental Treatment1 Intervention
Participants will receive an oral dose of LY3972406
Group III: PlaceboPlacebo Group1 Intervention
Participants will receive placebo.
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Plaque Psoriasis target specific pathways and molecules involved in the disease's pathogenesis, such as cytokines TNF-alpha, IL-17, and IL-23. TNF-alpha inhibitors (e.g., infliximab, adalimumab) block the activity of TNF-alpha to reduce inflammation.
IL-17 inhibitors (e.g., secukinumab, ixekizumab) and IL-23 inhibitors (e.g., guselkumab) target these interleukins to disrupt the inflammatory cascade. These treatments are essential for patients as they address the underlying immune mechanisms, leading to reduced symptoms and improved quality of life.
Trim21 promotes inflammation in keratinocytes of psoriatic patients.[Pathogenesis of psoriasis].Leukocyte extravasation as a target for anti-inflammatory therapy - Which molecule to choose?
Trim21 promotes inflammation in keratinocytes of psoriatic patients.[Pathogenesis of psoriasis].Leukocyte extravasation as a target for anti-inflammatory therapy - Which molecule to choose?
Find a Location
Who is running the clinical trial?
Eli Lilly and CompanyLead Sponsor
2,680 Previous Clinical Trials
3,466,309 Total Patients Enrolled
Study DirectorEli Lilly and Company